COVID-19 Mortality in the Colorado Center for Personalized Medicine Biobank
-
Published:2023-01-29
Issue:3
Volume:20
Page:2368
-
ISSN:1660-4601
-
Container-title:International Journal of Environmental Research and Public Health
-
language:en
-
Short-container-title:IJERPH
Author:
Brice Amanda N.1, Vanderlinden Lauren A.1, Marker Katie M.23, Mayer David34, Lin Meng34, Rafaels Nicholas4, Shortt Jonathan A.34ORCID, Romero Alex3, Lowery Jan T.14, Gignoux Christopher R.234, Johnson Randi K.134ORCID
Affiliation:
1. Department of Epidemiology, Colorado School of Public Health, Aurora, CO 80045, USA 2. Human Medical Genetics and Genomics Program, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA 3. Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA 4. Colorado Center for Personalized Medicine, Aurora, CO 80045, USA
Abstract
Over 6.37 million people have died from COVID-19 worldwide, but factors influencing COVID-19-related mortality remain understudied. We aimed to describe and identify risk factors for COVID-19 mortality in the Colorado Center for Personalized Medicine (CCPM) Biobank using integrated data sources, including Electronic Health Records (EHRs). We calculated cause-specific mortality and case-fatality rates for COVID-19 and common pre-existing health conditions defined by diagnostic phecodes and encounters in EHRs. We performed multivariable logistic regression analyses of the association between each pre-existing condition and COVID-19 mortality. Of the 155,859 Biobank participants enrolled as of July 2022, 20,797 had been diagnosed with COVID-19. Of 5334 Biobank participants who had died, 190 were attributed to COVID-19. The case-fatality rate was 0.91% and the COVID-19 mortality rate was 122 per 100,000 persons. The odds of dying from COVID-19 were significantly increased among older men, and those with 14 of the 61 pre-existing conditions tested, including hypertensive chronic kidney disease (OR: 10.14, 95% CI: 5.48, 19.16) and type 2 diabetes with renal manifestations (OR: 5.59, 95% CI: 3.42, 8.97). Male patients who are older and have pre-existing kidney diseases may be at higher risk for death from COVID-19 and may require special care.
Funder
UCHealth University of Colorado Anschutz Medical Campus
Subject
Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health
Reference30 articles.
1. An interactive web-based dashboard to track COVID-19 in real time;Dong;Lancet Infect. Dis.,2020 2. Johns Hopkins University & Medicine (2023, January 20). Mortality Analyses. Available online: https://coronavirus.jhu.edu/data/mortality. 3. (2023, January 20). The Sex, Gender and COVID-19 Project. Men, Sex, Gender, and COVID-19. Available online: https://globalhealth5050.org/the-sex-gender-and-covid-19-project/men-sex-gender-and-covid-19/. 4. National Trends of Cases of COVID-19 in Children Based on US State Health Department Data;Sisk;Pediatrics,2020 5. CDC COVID-19 Response Team, Bialek, S., Boundy, E., Bowen, V., Chow, N., Chon, A., Dowling, N., Ellington, S., Gierke, R., and Hall, A. (2020). Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19)—United States, February 12-March 16, 2020. MMWR Morb. Mortal. Wkly. Rep., 69, 343–346.
|
|